These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 30711576)
1. Luxturna: FDA documents reveal the value of a costly gene therapy. Darrow JJ Drug Discov Today; 2019 Apr; 24(4):949-954. PubMed ID: 30711576 [TBL] [Abstract][Full Text] [Related]
2. Voretigene neparvovec-rzyl (Luxturna) for inherited retinal dystrophy. Med Lett Drugs Ther; 2018 Mar; 60(1543):53-55. PubMed ID: 29635265 [No Abstract] [Full Text] [Related]
5. Lessons Learned from the Development of the First FDA-Approved Gene Therapy Drug, Voretigene Neparvovec-rzyl. Bennett J; Maguire AM Cold Spring Harb Perspect Med; 2023 May; 13(5):. PubMed ID: 36167727 [TBL] [Abstract][Full Text] [Related]
6. Voretigene Neparvovec: A Review in RPE65 Mutation-Associated Inherited Retinal Dystrophy. Kang C; Scott LJ Mol Diagn Ther; 2020 Aug; 24(4):487-495. PubMed ID: 32535767 [TBL] [Abstract][Full Text] [Related]
7. Voretigene neparvovec-rzyl for treatment of Ciulla TA; Hussain RM; Berrocal AM; Nagiel A Expert Opin Biol Ther; 2020 Jun; 20(6):565-578. PubMed ID: 32149547 [No Abstract] [Full Text] [Related]
12. Subretinal deposits in young patients treated with voretigene neparvovec-rzyl for RPE65-mediated retinal dystrophy. Lopez J; Borchert M; Lee TC; Nagiel A Br J Ophthalmol; 2023 Mar; 107(3):299-301. PubMed ID: 35835501 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of Voretigene Neparvovec-rzyl vs Standard Care for RPE65-Mediated Inherited Retinal Disease. Johnson S; Buessing M; O'Connell T; Pitluck S; Ciulla TA JAMA Ophthalmol; 2019 Oct; 137(10):1115-1123. PubMed ID: 31318398 [TBL] [Abstract][Full Text] [Related]
14. Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 3 and 4 Years. Maguire AM; Russell S; Chung DC; Yu ZF; Tillman A; Drack AV; Simonelli F; Leroy BP; Reape KZ; High KA; Bennett J Ophthalmology; 2021 Oct; 128(10):1460-1468. PubMed ID: 33798654 [TBL] [Abstract][Full Text] [Related]
15. Subretinal Injection of Voretigene Neparvovec-rzyl in a Patient With RPE65-Associated Leber's Congenital Amaurosis. Hussain RM; Tran KD; Maguire AM; Berrocal AM Ophthalmic Surg Lasers Imaging Retina; 2019 Oct; 50(10):661-663. PubMed ID: 31671202 [TBL] [Abstract][Full Text] [Related]
16. The first gene therapy for Ferraz Sallum JM; Godoy J; Kondo A; Kutner JM; Vasconcelos H; Maia A Ophthalmic Genet; 2022 Aug; 43(4):550-554. PubMed ID: 35416119 [TBL] [Abstract][Full Text] [Related]
17. Quantitative Autofluorescence Following Gene Therapy With Voretigene Neparvovec. Levi SR; Oh JK; de Carvalho JRL; Mahajan VB; Tsang SH; Sparrow JR JAMA Ophthalmol; 2020 Aug; 138(8):919-921. PubMed ID: 32556084 [No Abstract] [Full Text] [Related]
18. Frequency of Kahraman NS; Öner A; Özkul Y; Dündar M Turk J Ophthalmol; 2022 Aug; 52(4):270-275. PubMed ID: 36017377 [TBL] [Abstract][Full Text] [Related]